Pieris Announces Presentations at Upcoming R&D Conferences

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pieris Announces Presentations at Upcoming R&D Conferences

BOSTON, MA --(Marketwired - October 22, 2015) - Pieris Pharmaceuticals, Inc . ( NASDAQ : PIRS ), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform, announced today presentations at three R&D conferences in the month of November: The Society for Immunotherapy of Cancer (SITC), The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, and The PEGS Europe Summit.

The details for each presentation are as follows:

  • Protein Engineering Summit Europe (PEGS) , Lisbon, Portugal, November 2 - 6, 2015 at the EPIC SANA Lisboa Hotel
    • Presentation Time: Wednesday, November 4, 2015 at 4:15 pm in the Bispecifics and Novel Biotherapeutics track in the session "Bispecifics for Immuno-oncology"
    • Presentation: A Podium Presentation entitled "Bispecific Anticalin fusion proteins for localized targeting of immune cells for application in immuno-oncology"
  • Society for Immunotherapy of Cancer (SITC) , 30 th Anniversary Annual Meeting in National Harbor, MD, November 4 - 8, 2015, at the Gaylord National Hotel & Convention Center
    • Poster Session : November 6, 2015 from 6:15 pm to 7:30 pm and November 7, 2015 from 12:30 pm to 2:00 pm
    • Presentation: A poster presentation entitled "Costimulatory T-cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein" (Poster Number: 198)
  • AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics , Boston, MA, November 5 - 9, 2015 at the Hynes Convention Center
    • Poster Session : Sunday, November 8, 2015 from 12:30 pm to 3:30 pm, Poster Session C, Immune Modulators, Hall C-D
    • Presentation : A poster presentation entitled "Costimulatory T-cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein" (Abstract # C205)

Stephen Yoder, Pieris President and CEO, commented, "As we continue to advance our pipeline of immuno-oncology multispecifics, we're pleased to present a diverse set of emerging preclinical data at a number of prestigious conferences. The data will showcase the power of our Anticalin platform for the development of novel tumor-targeted immunotherapies with the potential for enhanced efficacy and safety."

About Pieris Pharmaceuticals:

Pieris is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat severe asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalins are a novel class of protein therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin ® , Anticalins ® are registered trademarks of Pieris. For more information visit www.pieris.com .

Forward Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; our liquidity and ability to fund our future operations; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov , including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and the Company's Quarterly Reports on Form 10-Q.

Company Contact: Pieris Pharmaceuticals, Inc. Darlene Deptula-Hicks SVP & Chief Financial Officer +1-603-553-5803 deptula@pieris.com Investor Relations Contact: The Trout Group Thomas Hoffmann +1-646-378-2931 thoffmann@troutgroup.com or The Del Mar Consulting Group, Inc. Robert Prag President +1-858-794-5000 bprag@delmarconsulting.com Media Inquiries: Gretchen Schweitzer +49 172 861 8540 gschweitzer@macbiocom.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 334

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 423

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 256

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 301

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 448

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 215

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 349

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 245

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 285

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 412

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading

Top 5 Most Recently Viewed Articles

TransAlta Announces Right to Convert Series G Preferred Shares

Updated Category News Views 124

Update on TransAlta's Series G Preferred Shares TransAlta Corporation (TSX: TA; NYSE: TAC) has shared important news about its cumulative redeemable rate reset first preferred shares, known as Series G. The company has decided not to exercise its right to redeem these shares on the upcoming conversion date. Details on the Conversion of Series G Shares Holders of Series G...

Continue Reading
Automotive Engine Oil Market Surge: Innovations and Challenges

Updated Category News Views 469

The Rising Tide of the Automotive Engine Oil Market The global automotive engine oil market is on a exciting trajectory, projected to grow significantly in the coming years. This growth can largely be attributed to the increasing number of vehicles on the roads and advancements in engine oil technology. Experts estimate that the market will grow by approximately USD 12.5...

Continue Reading
Understanding Ferguson Enterprises' Price-to-Earnings Ratio

Updated Category News Views 112

Ferguson Enterprises Inc. Recent Stock Performance As we delve into Ferguson Enterprises Inc. (NYSE: FERG), the current trading price stands at $227.06, reflecting a slight decrease of 0.71%. In the preceding month, the stock has experienced a drop of 10.00%. However, when we take a year-long view, it’s noteworthy that the stock has actually appreciated by 30.82%. This...

Continue Reading
Cyabra to Engage in Needham Growth Conference: What to Expect

Updated Category News Views 100

Cyabra to Engage in Needham Growth Conference Cyabra Ltd., a pioneering AI platform focused on the detection of real-time disinformation, is set to participate in an influential industry event: the 27th Annual Needham Growth Conference. This virtual conference presents an exciting opportunity for investors and stakeholders to connect with Cyabra's leadership, specifically...

Continue Reading
Job Market Frustrations: The Truth Behind 'Remote Work' Claims

Updated Category News Views 451

Job Seekers Faces Misleading Remote Work Claims Recently, stories shared online illustrate a frustrating trend in the job market, particularly concerning remote work commitments. Job seekers are collectively expressing outrage over interviews that promise flexible arrangements only to reveal hidden requirements for in-office presence. This alarming shift has spurr

Continue Reading